• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

News

Outcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis

7 de July de 2025
Blood. 2025 Jul 7:blood.2024027197. doi: 10.1182/blood.2024027197.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2025-07-07 10:00:002025-07-07 10:00:00Outcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis

Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee

3 de July de 2025
Lancet Haematol. 2025 Jul;12(7):e542-e554. doi: 10.1016/S2352-3026(25)00073-0.ABSTRACTAllogeneic…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2025-07-03 10:00:002025-07-03 10:00:00Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee

Correction: Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation

30 de June de 2025
Bone Marrow Transplant. 2025 Jun 30. doi: 10.1038/s41409-025-02664-5.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2025-06-30 10:00:002025-06-30 10:00:00Correction: Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation

Allogeneic haematopoietic cell transplant should still be considered as a curative option for relapsed/refractory large B-cell lymphoma, including in the CAR T-cell era

25 de June de 2025
Br J Haematol. 2025 Jun 25. doi: 10.1111/bjh.20217. Online ahead…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2025-06-25 10:00:002025-06-25 10:00:00Allogeneic haematopoietic cell transplant should still be considered as a curative option for relapsed/refractory large B-cell lymphoma, including in the CAR T-cell era

Corrigendum to ‘Clinical Practice Recommendations for Hematopoietic Cell Transplantation.’ Transplant Cell Ther. 2024 Sep;30(9):832-843

24 de June de 2025
Transplant Cell Ther. 2025 Jun 21:S2666-6367(25)01206-0. doi:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2025-06-24 10:00:002025-06-24 10:00:00Corrigendum to ‘Clinical Practice Recommendations for Hematopoietic Cell Transplantation.’ Transplant Cell Ther. 2024 Sep;30(9):832-843

RETRACTED: Cejuela et al. Metformin and Breast Cancer: Where Are We Now? Int. J. Mol. Sci. 2022, 23, 2705

13 de June de 2025
Int J Mol Sci. 2025 Jun 5;26(11):5407. doi: 10.3390/ijms26115407.ABSTRACTThe…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2025-06-13 10:00:002025-06-13 10:00:00RETRACTED: Cejuela et al. Metformin and Breast Cancer: Where Are We Now? Int. J. Mol. Sci. 2022, 23, 2705

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

11 de June de 2025
Blood. 2025 Jun 11:blood.2025028313. doi: 10.1182/blood.2025028313.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2025-06-11 10:00:002025-06-11 10:00:00High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma

5 de June de 2025
Blood Adv. 2025 Jun 5:bloodadvances.2024015274. doi: 10.1182/bloodadvances.2024015274.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2025-06-05 10:00:002025-06-05 10:00:00Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma

Autocrine TGF-β signaling promotes cell motility and chemokine secretion in an angiomyolipoma-derived cell model of lymphangioleiomyomatosis

1 de June de 2025
Am J Pathol. 2025 May 30:S0002-9440(25)00182-8. doi: 10.1016/j.ajpath.2025.04.019.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2025-06-01 10:00:002025-06-01 10:00:00Autocrine TGF-β signaling promotes cell motility and chemokine secretion in an angiomyolipoma-derived cell model of lymphangioleiomyomatosis

Setting up a CAR-T Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation

25 de May de 2025
Transplant Cell Ther. 2025 May 23:S2666-6367(25)01196-0. doi:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2025-05-25 10:00:002025-05-25 10:00:00Setting up a CAR-T Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation

Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

22 de May de 2025
Blood. 2025 May 22:blood.2025029234. doi: 10.1182/blood.2025029234.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2025-05-22 10:00:002025-05-22 10:00:00Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study

18 de May de 2025
Ann Oncol. 2025 May 16:S0923-7534(25)00200-5. doi: 10.1016/j.annonc.2025.05.008.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2025-05-18 10:00:002025-05-18 10:00:00Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
Page 10 of 87«‹89101112›»

Filter by categories

  • Alemany’s & Piulats’s lab (133)
  • Antolin's lab (36)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sin categoría (5)
  • Sureda's & Farre's Lab (312)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}